Article
Engineering, Biomedical
Diana G. Kulawiec, Tony Zhou, Jennifer L. Knopp, J. Geoffrey Chase
Summary: The study reveals that glycemic variability and glycemic response to carbohydrate intake of athletes increase after endurance exercise, while overnight glucose levels remain elevated. These metabolic effects can be quantified using commercially available CGM devices, encouraging further research on monitoring athletic recovery after intense exercise events.
BIOMEDICAL SIGNAL PROCESSING AND CONTROL
(2021)
Article
Biochemistry & Molecular Biology
Valeria Musso, Isabella Panfoli, Marcella Battaglini, Giorgia Brigati, Diego Minghetti, Chiara Andreato, Luca A. Ramenghi
Summary: Glycemic variability is common in preterm infants and can affect neurodevelopment. This study found that intermittent enteral feeding is better for glycemic control compared to continuous feeding. Optimizing nutritional management is crucial for the long-term health of preterm infants.
Article
Endocrinology & Metabolism
Caroline T. B. Juel, Thomas F. Dejgaard, Carsten P. Hansen, Jan H. Storkholm, Tina Vilsboll, Asger Lund, Filip K. Knop
Summary: The study evaluated glycemic variability in totally pancreatectomized patients and compared it with HbA(1c)-matched patients with long-standing type 1 diabetes. Results showed higher CONGA(60 min) and time spent above range in PX patients compared to T1D patients.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Hidenori Yoshii, Tomoya Mita, Naoto Katakami, Yosuke Okada, Takeshi Osonoi, Katsumi Aso, Akira Kurozumi, Satomi Wakasugi, Fumiya Sato, Ryota Ishii, Masahiko Gosho, Iichiro Shimomura, Hirotaka Watada
Summary: Higher HbA1c levels do not always protect against hypoglycemic episodes. Our data demonstrate that using CGM metrics to complement HbA1c monitoring is beneficial, especially in older people, users of insulin and/or sulfonylureas, and patients with chronic kidney disease.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Multidisciplinary Sciences
Caroline Wuyts, Caroline Simoens, Silvia Pinto, Koenraad Philippaert, Rudi Vennekens
Summary: Research using continuous glucose monitoring has shown that mice develop glucose adaptations similar to pregnant women during the full pregnancy period. Continuous glucose monitoring is a feasible, accurate, and safe method to track blood glucose levels in conscious, unstressed mice, providing valuable insights into the mechanisms of gestational diabetes mellitus.
SCIENTIFIC REPORTS
(2021)
Article
Biophysics
Inyoung Lee, David Probst, David Klonoff, Koji Sode
Summary: Diabetes mellitus is a chronic illness in the United States with approximately 120 million affected adults. Tight glycemic control is essential for managing diabetes and reducing the risk of complications. Continuous glucose monitoring systems are recognized as the ideal monitoring systems for diabetic patients.
BIOSENSORS & BIOELECTRONICS
(2021)
Article
Medicine, General & Internal
Sua Lee, Soyoung Lee, Kyeong Min Kim, Jong Ho Shin
Summary: This study aimed to determine the usefulness of continuous glucose monitoring (CGM) for glycemic control and glycemic variability stabilization in patients with diabetes undergoing hemodialysis. The results showed that continuous glucose monitoring could be a promising tool for individualizing treatment strategies.
FRONTIERS IN MEDICINE
(2023)
Article
Endocrinology & Metabolism
Pau Herrero, Antonia Alalitei, Monika Reddy, Pantelis Georgiou, Nick Oliver
Summary: The study proposes a robust method to determine the minimum duration of CGM data required for reporting times in ranges and other glycemic metrics, suggesting that certain metrics can be robustly assessed within a 4-week period, while others evaluating hypoglycemia require longer window lengths.
DIABETES TECHNOLOGY & THERAPEUTICS
(2021)
Article
Endocrinology & Metabolism
Rong Huang, Huiying Wang, Ziyang Shen, Tingting Cai, Yunting Zhou, Yuming Wang, Wenqing Xia, Bo Ding, Rengna Yan, Huiqin Li, Jindan Wu, Jianhua Ma
Summary: This study found that increased glycemic variability is associated with osteoporosis in patients with type 2 diabetes. Age, gender, BMI, LDL-C, and SUA were also identified as factors related to osteoporosis.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Nutrition & Dietetics
Jordi Merino, Inbar Linenberg, Kate M. Bermingham, Sajaysurya Ganesh, Elco Bakker, Linda M. Delahanty, Andrew T. Chan, Joan Capdevila Pujol, Jonathan Wolf, Haya Al Khatib, Paul W. Franks, Tim D. Spector, Jose M. Ordovas, Sarah E. Berry, Ana M. Valdes
Summary: This study aimed to evaluate the concordance of two simultaneously worn continuous glucose monitor (CGM) devices in measuring postprandial glycemic responses. The results showed a strong concordance between the two devices in measuring postprandial glycemic responses, suggesting their potential use in personalized nutrition.
AMERICAN JOURNAL OF CLINICAL NUTRITION
(2022)
Article
Endocrinology & Metabolism
Huiying Wang, Yunting Zhou, Xiaofang Zhai, Bo Ding, Ting Jing, Xiaofei Su, Huiqin Li, Jianhua Ma
Summary: The study aimed to evaluate glycemic control in adults with controlled type 2 diabetes mellitus using continuous glucose monitoring system during Basalin or Lantus administration. Lantus-treated patients showed lower 24-hour MBG, MAGE, and SDBG compared to the Basalin group. Insulin glargine Lantus may be a better choice for T2DM patients with HbA1c <= 7%.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Nutrition & Dietetics
Dylan J. J. Cooper, Sharon Zarabi, Brianna Farrand, Amanda Becker, Mitchell Roslin
Summary: This study investigated glucose fluctuations and insulin resistance patterns in normoglycemic participants with and without obesity. The results suggest that fasting insulin and HOMA-IR values may be more clinically useful than continuous glucose monitoring data alone.
FRONTIERS IN NUTRITION
(2022)
Article
Nutrition & Dietetics
Jiwoo Song, Tae Jung Oh, Yoonju Song
Summary: This study aimed to investigate the effects of meal types with varying carbohydrate levels on individual postprandial glycemic responses (PPGRs) and their associations with 14-day glycemic variability using continuous glucose monitoring (CGM) in young adults. The results showed that high responders had sustained peak glucose levels for a longer duration compared to low responders, especially in meals with carbohydrate contents above 50%. However, a meal with 45% carbohydrate content showed no correlation with either 14-day glycemic variability or control. Understanding the glycemic response to carbohydrate-rich meals and adopting a meal-based approach when planning diets are crucial for improving glycemic variability and control.
Article
Endocrinology & Metabolism
Eslam Montaser, Chiara Fabris, Boris Kovatchev
Summary: This study aimed to identify the principal dimensions of glycemic control and found that the glycemic-metric space has a true dimensionality of 2. Principal component analysis confirmed two essential metrics, treatment efficacy and treatment safety, which explained most of the variance.
DIABETES TECHNOLOGY & THERAPEUTICS
(2022)
Review
Clinical Neurology
Daniel Santana, Alejandra Mosteiro, Leire Pedrosa, Laura Llull, Ramon Torne, Sergi Amaro
Summary: Hyperglycaemia, hypoglycaemia, and glucose variability during the early brain injury (EBI) period of aneurysmal subarachnoid hemorrhage (aSAH) are associated with poor clinical outcome. However, it is unclear whether these associations are due to direct glucose-driven injury or if hyperglycaemia simply acts as a marker of initial severity. There is a need for comprehensive dynamic evaluations, such as continuous glucose monitoring devices (CMG), to better understand the relevance of glycaemia as a prognostic factor in aSAH.
FRONTIERS IN NEUROLOGY
(2022)
Article
Endocrinology & Metabolism
Gregory P. Forlenza, Tim Vigers, Cari Berget, Laurel H. Messer, Rayhan A. Lal, Marina Basina, David M. Maahs, Korey Hood, Bruce Buckingham, Darrell M. Wilson, R. Paul Wadwa, Kimberly A. Driscoll, Laura Pyle
Summary: This study developed and validated prognostic models for successful 12-month use of the first commercial HCL system based on baseline and 1- or 3-month data. Factors in the final model included baseline HbA1c, sex, ethnicity, 1- or 3-month Auto Mode use, Boluses per Day, and time in range. The prognostic models had very good predictive ability and may be useful for targeted interventions to promote success with new technologies.
DIABETES TECHNOLOGY & THERAPEUTICS
(2022)
Article
Endocrinology & Metabolism
Laya Ekhlaspour, Marissa Town, Dan Raghinaru, John W. Lum, Sue A. Brown, Bruce A. Buckingham
Summary: Using a closed-loop system can significantly improve time in range for patients with type 1 diabetes. Patients with different HbA1c levels showed improvements in blood sugar control through automated insulin adjustments, regardless of whether they had high or low blood sugar levels.
DIABETES TECHNOLOGY & THERAPEUTICS
(2022)
Correction
Endocrinology & Metabolism
D. C. Klonoff, B. Buckingham, J. S. Christiansen, V. M. Montori, W. Tamborlane, R. A. Vigersky, H. Wolpert
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Gregory P. Forlenza, Laya Ekhlaspour, Linda A. DiMeglio, Larry A. Fox, Henry Rodriguez, Dorothy I. Shulman, Kevin B. Kaiserman, David R. Liljenquist, John Shin, Scott W. Lee, Bruce A. Buckingham
Summary: The study found that using MiniMed (TM) 670G system in Auto Mode improved glycemic outcomes in young children with T1D compared to Manual Mode, including A1C levels, blood glucose control, and minimizing severe hypoglycemia. The results were similar to those seen in older children, adolescents, and adults with T1D using the system for the same duration of time.
PEDIATRIC DIABETES
(2022)
Article
Biochemical Research Methods
Felipe de Jesus Cortez, David Gebhart, Devangkumar Tandel, Peter Robinson, David Seftel, Darrell M. Wilson, David M. Maahs, Bruce A. Buckingham, Kevin W. P. Miller, Cheng-ting Tsai
Summary: This study presents an automated high-throughput multiplex islet autoantibody assay that utilizes agglutination-PCR chemistry for antibody detection. The automated system is capable of processing a large number of samples in a short time, requiring only a small volume of serum samples, making it suitable for large-scale analysis of islet autoantibodies.
Letter
Endocrinology & Metabolism
John P. Corbett, Liana Hsu, Sue A. Brown, Laura Kollar, Katelijn Vleugels, Bruce Buckingham, Marc D. Breton, Rayhan A. Lal
DIABETES OBESITY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Jordan E. Pinsker, Eyal Dassau, Sunil Deshpande, Dan Raghinaru, Bruce A. Buckingham, Yogish C. Kudva, Lori M. Laffel, Carol J. Levy, Mei Mei Church, Hannah Desrochers, Laya Ekhlaspour, Ravinder Jeet Kaur, Camilla Levister, Dawei Shi, John W. Lum, Craig Kollman, Francis J. Doyle, iDCL Trial Res Grp
Summary: The automated adaptation of insulin delivery settings did not significantly improve time-in-range in this well-controlled population of diabetes patients. Additional studies and further refinement of the adaptation system are needed, especially in populations with different degrees of baseline glycemic control, who may benefit more from adaptation.
DIABETES TECHNOLOGY & THERAPEUTICS
(2022)
Article
Endocrinology & Metabolism
Ron Brazg, Satish K. Garg, Anuj Bhargava, James R. Thrasher, Kashif Latif, Bruce W. Bode, Timothy S. Bailey, Barry S. Horowitz, Arvind Cavale, Yogish C. Kudva, Kevin B. Kaiserman, George Grunberger, John Chip Reed, Sarnath Chattaraj, Gina Zhang, John Shin, Vivian Chen, Scott W. Lee, Toni L. Cordero, Andrew S. Rhinehart, Robert A. Vigersky, Bruce A. Buckingham
Summary: This trial evaluated the safety and performance of a new extended-wear infusion set when used for 7 days by adults with type 1 diabetes. The results showed that the extended-wear infusion set was safe and rated with high satisfaction by patients, without adversely affecting glycemic control.
DIABETES TECHNOLOGY & THERAPEUTICS
(2022)
Article
Endocrinology & Metabolism
Bruce Buckingham, Jennifer Sherr, Steven J. Prestrelski, Valentina Conoscenti
Summary: The study aims to assess the efficacy, pharmacodynamics, pharmacokinetics, safety, and tolerability of a ready-to-use glucagon formulation in youth with type 1 diabetes. The results show that the formulation effectively reverses low blood glucose concentrations in youth with type 1 diabetes.
PEDIATRIC DIABETES
(2022)
Article
Endocrinology & Metabolism
Laya Ekhlaspour, Dan Raghinaru, Gregory P. Forlenza, Elvira Isganaitis, Yogish C. Kudva, David W. Lam, Camilla Levister, Grenye O'Malley, Mei Mei Church, John W. Lum, Bruce Buckingham, Sue A. Brown
Summary: The study investigated the potential benefits of automated insulin delivery among individuals with type 1 diabetes, regardless of their baseline device use or CGM status. The results showed that the closed-loop control system significantly improved glycemic outcomes in both insulin pump and MDI users with or without CGM.
JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY
(2023)
Article
Endocrinology & Metabolism
Kevin T. Nguyen, Nicole Y. Xu, Bruce A. Buckingham, Sarnath Chattaraj, Ohad Cohen, Lutz Heinemann, John Pickup, Jannet Svensson, Robert A. Vigersky, Jenise C. Wong, Ralph Ziegler
Summary: Continuous subcutaneous insulin infusion (CSII) therapy is gaining popularity due to its convenient insulin delivery, precise dosing, easy adjustments, and integration with continuous glucose monitors. However, technology for insulin infusion sets (IISs) has not kept pace with advancements in insulin pump hardware and software, posing challenges to CSII. To address these barriers and showcase advancements in longer wear IISs, a symposium was held, featuring experts in the field and covering topics such as insulin pump therapy advancements, efficacy of longer wear infusion sets, and innovation in reducing waste.
JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY
(2022)
Article
Endocrinology & Metabolism
Jennifer L. Sherr, Bruce W. Bode, Gregory P. Forlenza, Lori M. Laffel, Melissa J. Schoelwer, Bruce A. Buckingham, Amy B. Criego, Daniel J. DeSalvo, Sarah A. MacLeish, David W. Hansen, Trang T. Ly
Summary: This study evaluated the use of the Omnipod 5 Automated Insulin Delivery System in very young children with type 1 diabetes. The results showed that the system was safe to use and led to improved glycemic control and reduced hypoglycemia in the participants.
Review
Endocrinology & Metabolism
Moshe Phillip, Revital Nimri, Richard M. Bergenstal, Katharine Barnard-Kelly, Thomas Danne, Roman Hovorka, Boris P. Kovatchev, Laurel H. Messer, Christopher G. Parkin, Louise Ambler-Osborn, Stephanie A. Amiel, Lia Bally, Roy W. Beck, Sarah Biester, Torben Biester, Julia E. Blanchette, Emanuele Bosi, Charlotte K. Boughton, Marc D. Breton, Sue A. Brown, Bruce A. Buckingham, Albert Cai, Anders L. Carlson, Jessica R. Castle, Pratik Choudhary, Kelly L. Close, Claudio Cobelli, Amy B. Criego, Elizabeth Davis, Carine de Beaufort, Martin de Bock, Daniel J. DeSalvo, J. Hans DeVries, Klemen Dovc, Francis J. Doyle, Laya Ekhlaspour, Naama Fisch Shvalb, Gregory P. Forlenza, Geraldine Gallen, Satish K. Garg, Dana C. Gershenoff, Linda A. Gonder-Frederick, Ahmad Haidar, Sara Hartnell, Lutz Heinemann, Simon Heller, Irl B. Hirsch, Korey K. Hood, Diana Isaacs, David C. Klonoff, Olga Kordonouri, Aaron Kowalski, Lori Laffel, Julia Lawton, Rayhan A. Lal, Lalantha Leelarathna, David M. Maahs, Helen R. Murphy, Kirsten Norgaard, David O'Neal, Sean Oser, Tamara Oser, Eric Renard, Michael C. Riddell, David Rodbard, Steven J. Russell, Desmond A. Schatz, Viral N. Shah, Jennifer L. Sherr, Gregg D. Simonson, R. Paul Wadwa, Candice Ward, Stuart A. Weinzimer, Emma G. Wilmot, Tadej Battelino
Summary: The global prevalence of diabetes continues to be a challenge and the advances in automated insulin delivery (AID) technologies have shown to be safe and effective in helping patients achieve their glycemic goals. However, there is a lack of guidance for clinicians on using AID systems in clinical settings.
Article
Endocrinology & Metabolism
Satish K. Garg, George Grunberger, Ruth Weinstock, Margaret L. Lawson, Irl B. Hirsch, Linda A. DiMeglio, Rodica Pop-Busui, Athena Philis-Tsimikas, Mark Kipnes, David R. Liljenquist, Ronald L. Brazg, Yogish C. Kudva, Bruce A. Buckingham, Janet B. McGill, Anders L. Carlson, Amy B. Criego, Mark P. Christiansen, Kevin B. Kaiserman, Kurt J. Griffin, Greg P. Forlenza, Bruce W. Bode, Robert H. Slover, Ashleigh Keiter, Chenxiao Ling, Briggitte Marinos, Toni L. Cordero, John Shin, Scott W. Lee, Andrew S. Rhinehart, Robert A. Vigersky
Summary: This study evaluates the safety and effectiveness of MiniMed 670G hybrid closed loop (HCL) in comparison with continuous subcutaneous insulin infusion (CSII) therapy for individuals with type 1 diabetes (T1D). The results show that HCL intervention significantly improves A1C levels and reduces the percentage of time spent with blood glucose below 70 mg/dL, with good safety profile.
DIABETES TECHNOLOGY & THERAPEUTICS
(2023)
Review
Endocrinology & Metabolism
Tadej Battelino, Charles M. Alexander, Stephanie A. Amiel, Guillermo Arreaza-Rubin, Roy W. Beck, Richard M. Bergenstal, Bruce A. Buckingham, James Carroll, Antonio Ceriello, Elaine Chow, Pratik Choudhary, Kelly Close, Thomas Danne, Sanjoy Dutta, Robert Gabbay, Satish Garg, Julie Heverly, Irl B. Hirsch, Tina Kader, Julia Kenney, Boris Kovatchev, Lori Laffel, David Maahs, Chantal Mathieu, Didac Mauricio, Revital Nimri, Rimei Nishimura, Mauro Scharf, Stefano Del Prato, Eric Renard, Julio Rosenstock, Banshi Saboo, Kohjiro Ueki, Guillermo E. Umpierrez, Stuart A. Weinzimer, Moshe Phillip
Summary: Randomised controlled trials and other prospective clinical studies have traditionally used HbA1c as a measure of average blood glucose levels, but with the increasing use of continuous glucose monitoring (CGM), CGM-derived metrics are being considered for use in these studies. This consensus statement recommends the use of CGM data in clinical studies to provide additional clinical information beyond HbA1c. Standardizing the collection and reporting of CGM data in clinical trials can enhance the interpretability of the data and inform therapeutic decisions related to hypoglycaemia, postprandial hyperglycaemia, and glucose variability.
LANCET DIABETES & ENDOCRINOLOGY
(2023)